Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 14/20 | 0.66 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.44 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233422 | 0.92 | FKBP1A (0.74) | FKBP1AMMP2ANPEPABCC1FKBP4 | |
| SCHEMBL1233420 | 0.92 | FKBP1A (0.74) | FKBP1AMMP2ANPEPABCC1FKBP4 | |
| SCHEMBL5966161 | 0.91 | FKBP1A (0.80) | FKBP1AABCC1FKBP4FKBP5 | |
| SCHEMBL7155851 | 0.91 | FKBP1A (0.80) | FKBP1AABCC1FKBP4FKBP5 | |
| Hydroxyamine SCHEMBL5274861 | 0.84 | GAA (0.53) | FKBP1AMMP2ANPEPGAAALDH1A1 | |
| Hydroxyamine SCHEMBL5274854 | 0.84 | GAA (0.53) | FKBP1AMMP2ANPEPGAAALDH1A1 | |
| SCHEMBL14407836 | 0.79 | FKBP1A (0.63) | FKBP1AMMP2ANPEPGAAALDH1A1 | |
| SCHEMBL5966113 | 0.79 | FKBP1A (0.63) | FKBP1AMMP2ANPEPALDH1A1FKBP5 | |
| SCHEMBL11998537 | 0.78 | FKBP1A (0.56) | FKBP1AMMP2ANPEPGAAALDH1A1 | |
| SCHEMBL1233000 | 0.77 | FKBP1A (0.73) | FKBP1AABCC1FKBP4FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544976-B1 | Treating disorders characterized by neuronal damage caused by disease or trauma, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, diabetic neuropathy and Bell's palsy. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2001004091-A1 | NEUROTROPHIC 2-AZETIDINECARBOXYLIC ACID DERIVATIVES, AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |